Literature DB >> 27849170

HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism.

Todd Bradley1,2, Guang Yang3, Olga Ilkayeva4, T Matt Holl3, Ruijun Zhang5, Jinsong Zhang5, Sampa Santra6, Christopher B Fox7, Steve G Reed7, Robert Parks5, Cindy M Bowman5, Hilary Bouton-Verville5, Laura L Sutherland5, Richard M Scearce5, Nathan Vandergrift5,2, Thomas B Kepler8, M Anthony Moody5,9, Hua-Xin Liao5, S Munir Alam5,2, Roger McLendon4, Jeffrey I Everitt4, Christopher B Newgard9, Laurent Verkoczy5,2,4, Garnett Kelsoe1,3, Barton F Haynes1,2,4.   

Abstract

The HIV-1 envelope protein (Env) has evolved to subvert the host immune system, hindering viral control by the host. The tryptophan metabolic enzyme kynureninase (KYNU) is mimicked by a portion of the HIV Env gp41 membrane proximal region (MPER) and is cross-reactive with the HIV broadly neutralizing Ab (bnAb) 2F5. Molecular mimicry of host proteins by pathogens can lead to autoimmune disease. In this article, we demonstrate that neither the 2F5 bnAb nor HIV MPER-KYNU cross-reactive Abs elicited by immunization with an MPER peptide-liposome vaccine in 2F5 bnAb VHDJH and VLJL knock-in mice and rhesus macaques modified KYNU activity or disrupted tissue tryptophan metabolism. Thus, molecular mimicry by HIV-1 Env that promotes the evasion of host anti-HIV-1 Ab responses can be directed toward nonfunctional host protein epitopes that do not impair host protein function. Therefore, the 2F5 HIV Env gp41 region is a key and safe target for HIV-1 vaccine development.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27849170      PMCID: PMC5136304          DOI: 10.4049/jimmunol.1601484

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

1.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

2.  Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

Authors:  Rui Kong; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Thomas Lemmin; Kevin Liu; Gabriel Ozorowski; Cinque Soto; Justin D Taft; Robert T Bailer; Evan M Cale; Lei Chen; Chang W Choi; Gwo-Yu Chuang; Nicole A Doria-Rose; Aliaksandr Druz; Ivelin S Georgiev; Jason Gorman; Jinghe Huang; M Gordon Joyce; Mark K Louder; Xiaochu Ma; Krisha McKee; Sijy O'Dell; Marie Pancera; Yongping Yang; Scott C Blanchard; Walther Mothes; Dennis R Burton; Wayne C Koff; Mark Connors; Andrew B Ward; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2016-05-13       Impact factor: 47.728

3.  Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls.

Authors:  Laurent Verkoczy; Yao Chen; Hilary Bouton-Verville; Jinsong Zhang; Marilyn Diaz; Jennifer Hutchinson; Ying-Bin Ouyang; S Munir Alam; T Matt Holl; Kwan-Ki Hwang; Garnett Kelsoe; Barton F Haynes
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

4.  Polyreactivity and autoreactivity among HIV-1 antibodies.

Authors:  Mengfei Liu; Guang Yang; Kevin Wiehe; Nathan I Nicely; Nathan A Vandergrift; Wes Rountree; Mattia Bonsignori; S Munir Alam; Jingyun Gao; Barton F Haynes; Garnett Kelsoe
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

5.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

7.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

8.  Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Science       Date:  1985-11-29       Impact factor: 47.728

9.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

10.  Antibodies to the RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein A1 Colocalize to Stress Granules Resulting in Altered RNA and Protein Levels in a Model of Neurodegeneration in Multiple Sclerosis.

Authors:  Joshua N Douglas; Lidia A Gardner; Hannah E Salapa; Michael C Levin
Journal:  J Clin Cell Immunol       Date:  2016-03-22
View more
  4 in total

Review 1.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

Review 2.  Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Authors:  Laurent Verkoczy
Journal:  Adv Immunol       Date:  2017       Impact factor: 3.543

Review 3.  Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.

Authors:  Joel Finney; Garnett Kelsoe
Journal:  Retrovirology       Date:  2018-07-28       Impact factor: 4.602

Review 4.  Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Authors:  Luis M Molinos-Albert; Bonaventura Clotet; Julià Blanco; Jorge Carrillo
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.